SHELTON, Conn., Sept. 5, 2018 /PRNewswire/ -- NanoViricides,
Inc. (NYSE Amer: NNVC) (the "Company"), a
global leader in developing nanomedicines to attack viruses,
announced today that it will be presenting at the 20th Annual
Rodman & Renshaw Global Investment Conference, sponsored by
H.C. Wainwright & Co., LLC. The conference is being held on
September 4-6, 2018 at the St. Regis
New York Hotel in New York
City.
Dr. Anil Diwan, President and Chairman of the Board of
NanoViricides, will present a corporate overview and discuss the
Company's progress in taking its first drug candidate into human
clinical trials. He will also introduce the Company's new CEO, Dr.
Irach Taraporewala. The presentation is scheduled for 3:25pm ET on
Thursday, September 6th, 2018.
The Company has updated its corporate "fact sheet", or brochure,
and it is available on the Company's website at
www.nanoviricides.com.
The Company has a broad and deep pipeline of drug candidates
based on its unique, post-immunotherapeutic
"bind-encapsulate-destroy" "nanoviricide®" technology platform,
that addresses a market space of $40
Billion to $70 Billion. The
Company is currently focused on developing topical skin creams and
eye drops in the HerpeCide™ program to treat infections caused by
VZV, HSV-1, and HSV-2 herpesviruses, towards regulatory approvals.
These drug candidates leverage significant amounts of common
technologies, thereby enabling the Company to maximize return on
investments (ROI).
The Company has previously reported that its lead anti-VZV drug
candidates in the HerpeCide™ program have been found to be highly
effective against VZV infection of human skin patch organ culture
studies. These candidates were also found to be highly effective in
cell culture studies. In addition, these candidates were found to
be effective in ameliorating pain sensations in an animal model of
abnormal (neuropathic) pain. A characteristic excruciating pain is
a debilitating pathology of shingles presentation. Thus a direct
pain-reducing effect of the Company's anti-shingles drug candidates
would be very important in ameliorating the pathology of shingles,
in addition to the already demonstrated significant antiviral
effect.
There are currently no approved treatments for shingles, PHN, or
chickenpox, representing a commercially valuable unmet medical
need. All of these are diseases caused by VZV. A highly effective
treatment of shingles that would result in reduction in the
duration and severity of PHN cases has been estimated to have a
potential market size in the range of billions of dollars, even
after the recent introduction of the new Shingrix vaccine. There
are approximately 500,000 to 1 Million episodes of shingles
hospitalization cases annually in the
United States alone. Approximately 18% of patients overall,
and as many as 30-50% of older patients with shingles, are
estimated to have PHN. This represents more than 200,000 cases of
PHN annually in the USA alone.
Such VZV complications can cause extended hospitalization in about
4% of shingles patients overall, with an average estimated cost as
high as $20,000 per hospitalized
patient.
The Company has also found that these candidates were extremely
safe in a preliminary rat safety/toxicology study. This has led to
a redesign of the IND-enabling Safety/Toxicology study ("Tox
Package") to be performed at the "maximum feasible dose" (MFD)
level. This is estimated to require multi-kilogram quantities of
the drug candidates. The Company has recently started production of
the necessary quantities of the drug candidate at our cGMP-capable
facility in Shelton, CT. The
Company expects to begin "Tox Package" studies once the drug is
manufactured in the multi-kg quantities needed and is already in
negotiation with a CRO site for the study. The acute dermal
safety/tox study is expected to be of a relatively short duration
and we anticipate filing an IND once the report is available.
All of our drug candidates are based on broad and exclusive
licenses in perpetuity from TheraCour Pharma, Inc. A license for
VZV and the remaining herpesviruses is in progress. HSV-1 and HSV-2
are already licensed, as well as many other viruses including all
influenzas, HIV, Dengue, Ebola/Marburg, among others. For further
details, please refer to our quarterly and annual reports.
Shingles is caused by reactivation of the Varicella Zoster Virus
(VZV, aka human herpesvirus-3 or HHV-3). A chickenpox (i.e.
varicella) infection in childhood leads to the virus becoming
latent in the nervous system. At an older age, or when immunity
against this resident latent virus decreases, the virus replicates
in the nerve cells, and bursts out of the nerve endings infecting
neighboring skin cells, thus causing a typical shingles rash. The
nerve injury caused by the virus leads to a characteristic
excruciating and debilitating pain. The shingles rash may continue
to expand for several days, and then subsides in about three weeks
in an uncomplicated case. The VZV-associated neuropathic pain does
not resolve quickly, and may continue even after the rash has
resolved (hence called PHN), for several months to, in rare cases,
years.
About NanoViricides:
NanoViricides, Inc.
(www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
viral therapy. The Company's novel nanoviricide® class
of drug candidates are designed to specifically attack enveloped
virus particles and to dismantle them. The Company is developing
drugs against a number of viral diseases including H1N1 swine flu,
H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes,
viral diseases of the eye including EKC and herpes keratitis,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nanoviricides-inc-to-present-at-20th-annual-rodman--renshaw-conference-in-nyc-on-sept-6th-300706905.html
SOURCE NanoViricides, Inc.